A review of the cardiovascular and anti-atherogenic effects of ghrelin

Current Pharmaceutical Design

Volumn 19, Issue 27, 2013, Pages 4953-4963

  Rizzo, Manfredi ^a,b   Rizvi, Ali A ^c   Sudar, Emina ^d   Soskic, Sanja ^d   Obradovic, Milan ^d   Montalto, Giuseppe ^a   Boutjdir, Mohamed ^e,f   Mikhailidis, Dimitri P ^g   Isenovic, Esma R ^d  

^a UNIVERSITY OF PALERMO   (Italy)

^b Euro Mediterranean Institute of Science and Technology   (Italy)

^c UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF BELGRADE   (Serbia)

^e DEPARTMENT OF VETERANS AFFAIRS   (United States)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Atherosclerosis; Cardiovascular diseases; Cardiovascular system; Ghrelin; Type 2 diabetes mellitus

Indexed keywords

ADENOSINE PHOSPHATE; ATORVASTATIN; CALCIUM ION; CORTICOTROPIN; CYCLIC AMP; DIACYLGLYCEROL; FENOFIBRATE; GEMFIBROZIL; GHRELIN; GHRELIN RECEPTOR; GLUCOSE; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE RELEASING FACTOR RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; HYDROCORTISONE; INOSITOL TRISPHOSPHATE; INSULIN; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; NATEGLINIDE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE; PHOSPHOLIPASE C; POTASSIUM ION; PROLACTIN; PROTEIN KINASE B; PROTEIN KINASE C; REPAGLINIDE; TETRAHYDROLIPSTATIN;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR EFFECT; CARDIOVASCULAR SYSTEM; DIET RESTRICTION; DRUG MEGADOSE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GROWTH HORMONE RELEASE; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE INJURY; HEART PROTECTION; HUMAN; HYPERTENSION; HYPOGLYCEMIA; HYPOLIPEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN RESPONSE; ISCHEMIC HEART DISEASE; LIPID METABOLISM; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; VASODILATATION;

ANIMALS; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; DIABETES MELLITUS, TYPE 2; EVIDENCE-BASED MEDICINE; GASTRIC MUCOSA; GHRELIN; HUMANS; HYPERGLYCEMIA; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; INSULIN; LIPID METABOLISM;

EID: 84881348966     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319270018     Document Type: Review

References (149)

1. Argetsinger LS, Carter-Su C. Mechanism of signaling by growth hormone receptor. Physiol Rev 1996; 76: 1089-107.
2. Carter-Su C, King AP, Argetsinger LS, et al. Signalling pathway of GH. Endocr J 1996; 43 Suppl: S65-70.
3. Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996; 273: 974-7.
4. Korbonits M, Ciccarelli E, Ghigo E, Grossman AB. The growth hormone secretagogue receptor. Growth Horm IGF Res 1999; 9 Suppl A: 93-9.
5. Smith RG, Feighner S, Prendergast K, Guan X, Howard A. A New Orphan Receptor Involved in Pulsatile Growth Hormone Release. Trends Endocrinol Metab 1999; 10: 128-35.
6. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormonereleasing acylated peptide from stomach. Nature 1999; 402: 656-60.
7. Hosoda H, Kojima M, Matsuo H, Kangawa K. Ghrelin and desacyl ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem Biophys Res Commun 2000; 279: 909-13.
8. Korbonits M, Goldstone AP, Gueorguiev M, Grossman AB. Ghrelin--a hormone with multiple functions. Front Neuroendocrinol 2004; 25: 27-68.
9. van der Lely AJ, Tschop M, Heiman ML, Ghigo E. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 2004; 25: 426-57.
10. Stanley S, Wynne K, McGowan B, Bloom S. Hormonal regulation of food intake. Physiol Rev 2005; 85: 1131-58.
11. Havel PJ. Peripheral signals conveying metabolic information to the brain: short-term and long-term regulation of food intake and energy homeostasis. Exp Biol Med (Maywood) 2001; 226: 963-77.
12. Schwartz MW, Woods SC, Porte D, Jr., Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature 2000; 404: 661-71.
13. Katsiki N, Mikhailidis DP, Gotzamani-Psarrakou A, Yovos JG, Karamitsos D. Effect of various treatments on leptin, adiponectin, ghrelin and neuropeptide Y in patients with type 2 diabetes mellitus. Expert opinion on therapeutic targets 2011; 15: 401-20.
14. Paraskevas KI, Liapis CD, Mikhailidis DP. Leptin: a promising therapeutic target with pleiotropic action besides body weight regulation. Curr Drug Targets 2006; 7: 761-71.
15. Sudar E, Soskic S, Zaric B, et al. Ghrelin, Obesity and Atherosclerosis Hauppauge NY 11788-3619 United States of America: Nova Science Publishers, Inc.; 2012; Available from: https://www.novapublishers.com/catalog/product_info.php?products_id= 27602.
16. Levin BE, Dunn-Meynell AA. Dysregulation of arcuate nucleus preproneuropeptide Y mRNA in diet-induced obese rats. Am J Physiol 1997; 272: R1365-70.
17. Scarpace PJ, Zhang Y. Leptin resistance: a prediposing factor for diet-induced obesity. Am J Physiol Regul Integr Comp Physiol 2009; 296: R493-500.
18. Seufert J, Kieffer TJ, Leech CA, et al. Leptin suppression of insulin secretion and gene expression in human pancreatic islets: implications for the development of adipogenic diabetes mellitus. J Clin Endocrinol Metab 1999; 84: 670-6.
19. Seufert J. Leptin effects on pancreatic beta-cell gene expression and function. Diabetes 2004; 53 Suppl 1: S152-8.
20. Stanic D, Brumovsky P, Fetissov S, et al. Characterization of neuropeptide Y2 receptor protein expression in the mouse brain. I. Distribution in cell bodies and nerve terminals. J Comp Neurol 2006; 499: 357-90.
21. Kos K, Harte AL, James S, et al. Secretion of neuropeptide Y in human adipose tissue and its role in maintenance of adipose tissue mass. Am J Physiol Endocrinol Metab 2007; 293: E1335-40.
22. Rigalleau V, Delafaye C, Baillet L, et al. Composition of insulininduced body weight gain in diabetic patients: a bio-impedance study. Diabetes & metabolism 1999; 25: 321-8.
23. Hickey MS, Israel RG, Gardiner SN, et al. Gender differences in serum leptin levels in humans. Biochem Mol Med 1996; 59: 1-6.
24. Cummings DE, Purnell JQ, Frayo RS, et al. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001; 50: 1714-9.
25. Tschop M, Wawarta R, Riepl RL, et al. Post-prandial decrease of circulating human ghrelin levels. J Endocrinol Invest 2001; 24: RC19-21.
26. McCowen KC, Maykel JA, Bistrian BR, Ling PR. Circulating ghrelin concentrations are lowered by intravenous glucose or hyperinsulinemic euglycemic conditions in rodents. J Endocrinol 2002; 175: R7-11.
27. Dzaja A, Dalal MA, Himmerich H, et al. Sleep enhances nocturnal plasma ghrelin levels in healthy subjects. Am J Physiol Endocrinol Metab 2004; 286: E963-7.
28. Yildiz BO, Suchard MA, Wong ML, McCann SM, Licinio J. Alterations in the dynamics of circulating ghrelin, adiponectin, and leptin in human obesity. Proc Natl Acad Sci USA 2004; 101: 10434-9.
29. Sato T, Nakamura Y, Shiimura Y, et al. Structure, regulation and function of ghrelin. J Biochem 2012; 151: 119-28.
30. Erdmann J, Lippl F, Schusdziarra V. Differential effect of protein and fat on plasma ghrelin levels in man. Regul Pept 2003; 116: 101-7.
31. Greenman Y, Golani N, Gilad S, et al. Ghrelin secretion is modulated in a nutrient-and gender-specific manner. Clin Endocrinol (Oxf) 2004; 60: 382-8.
32. Kojima M, Kangawa K. Ghrelin: structure and function. Physiol Rev 2005; 85: 495-522.
33. Arvat E, Di Vito L, Broglio F, et al. Preliminary evidence that Ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans. J Endocrinol Invest 2000; 23: 493-5.
34. Adeghate E, Ponery AS. Ghrelin stimulates insulin secretion from the pancreas of normal and diabetic rats. J Neuroendocrinol 2002; 14: 555-60.
35. Date Y, Murakami N, Kojima M, et al. Central effects of a novel acylated peptide, ghrelin, on growth hormone release in rats. Biochem Biophys Res Commun 2000; 275: 477-80.
36. Smith RG, Van der Ploeg LH, Howard AD, et al. Peptidomimetic regulation of growth hormone secretion. Endocr Rev 1997; 18: 621-45.
37. Schaller G, Schmidt A, Pleiner J, et al. Plasma ghrelin concentrations are not regulated by glucose or insulin: a doubleblind, placebo-controlled crossover clamp study. Diabetes 2003; 52: 16-20.
38. Tschop M, Weyer C, Tataranni PA, et al. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001; 50: 707-9.
39. Shiiya T, Nakazato M, Mizuta M, et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 2002; 87: 240-4.
40. Katsuki A, Urakawa H, Gabazza EC, et al. Circulating levels of active ghrelin is associated with abdominal adiposity, hyperinsulinemia and insulin resistance in patients with type 2 diabetes mellitus. Eur J Endocrinol 2004; 151: 573-7.
41. Couce ME, Cottam D, Esplen J, et al. Potential role of hypothalamic ghrelin in the pathogenesis of human obesity. J Endocrinol Invest 2006; 29: 599-605.
42. Ueno H, Shiiya T, Mizuta M, Mondal SM, Nakazato M. Plasma ghrelin concentrations in different clinical stages of diabetic complications and glycemic control in Japanese diabetics. Endocr J 2007; 54: 895-902.
43. Fruhbeck G, Rotellar F, Hernandez-Lizoain JL, et al. Fasting plasma ghrelin concentrations 6 months after gastric bypass are not determined by weight loss or changes in insulinemia. Obesity surgery 2004; 14: 1208-15.
44. Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. Nature 2001; 409: 194-8.
45. Kamegai J, Tamura H, Shimizu T, et al. Chronic central infusion of ghrelin increases hypothalamic neuropeptide Y and Agouti-related protein mRNA levels and body weight in rats. Diabetes 2001; 50: 2438-43.
46. Lawrence CB, Snape AC, Baudoin FM, Luckman SM. Acute central ghrelin and GH secretagogues induce feeding and activate brain appetite centers. Endocrinology 2002; 143: 155-62.
47. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000; 407: 908-13.
48. Zhang G, Yin X, Qi Y, et al. Ghrelin and cardiovascular diseases. Curr Cardiol Rev 2010; 6: 62-70.
49. Fazio S, Sabatini D, Capaldo B, et al. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med 1996; 334: 809-14.
50. Broglio F, Benso A, Valetto MR, et al. Growth hormoneindependent cardiotropic activities of growth hormone-releasing peptides in normal subjects, in patients with growth hormone deficiency, and in patients with idiopathic or ischemic dilated cardiomyopathy. Endocrine 2001; 14: 105-8.
51. Muccioli G, Broglio F, Valetto MR, et al. Growth hormonereleasing peptides and the cardiovascular system. Ann Endocrinol (Paris) 2000; 61: 27-31.
52. Tivesten A, Bollano E, Caidahl K, et al. The growth hormone secretagogue hexarelin improves cardiac function in rats after experimental myocardial infarction. Endocrinology 2000; 141: 60-6.
53. Nagaya N, Moriya J, Yasumura Y, et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 2004; 110: 3674-9.
54. Nagaya N, Uematsu M, Kojima M, et al. Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation 2001; 104: 1430-5.
55. Shimizu Y, Nagaya N, Teranishi Y, et al. Ghrelin improves endothelial dysfunction through growth hormone-independent mechanisms in rats. Biochem Biophys Res Commun 2003; 310: 830-5.
56. Bodart V, Bouchard JF, McNicoll N, et al. Identification and characterization of a new growth hormone-releasing peptide receptor in the heart. Circ Res 1999; 85: 796-802.
57. Gnanapavan S, Kola B, Bustin SA, et al. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 2002; 87: 2988.
58. Baldanzi G, Filigheddu N, Cutrupi S, et al. Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J Cell Biol 2002; 159: 1029-37.
59. Pettersson I, Muccioli G, Granata R, et al. Natural (ghrelin) and synthetic (hexarelin) GH secretagogues stimulate H9c2 cardiomyocyte cell proliferation. J Endocrinol 2002; 175: 201-9.
60. Nagaya N, Kojima M, Uematsu M, et al. Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J Physiol Regul Integr Comp Physiol 2001; 280: R1483-7.
61. Nagaya N, Miyatake K, Uematsu M, et al. Hemodynamic, renal, and hormonal effects of ghrelin infusion in patients with chronic heart failure. J Clin Endocrinol Metab 2001; 86: 5854-9.
62. Katugampola SD, Pallikaros Z, Davenport AP. [125I-His(9)]-ghrelin, a novel radioligand for localizing GHS orphan receptors in human and rat tissue: up-regulation of receptors with athersclerosis. Br J Pharmacol 2001; 134: 143-9.
63. Nagaya N, Kangawa K. Ghrelin improves left ventricular dysfunction and cardiac cachexia in heart failure. Curr Opin Pharmacol 2003; 3: 146-51.
64. Nagaya N, Kangawa K. Ghrelin, a novel growth hormone-releasing peptide, in the treatment of chronic heart failure. Regul Pept 2003; 114: 71-7.
65. Frascarelli S, Ghelardoni S, Ronca-Testoni S, Zucchi R. Effect of ghrelin and synthetic growth hormone secretagogues in normal and ischemic rat heart. Basic Res Cardiol 2003; 98: 401-5.
66. Tesauro M, Schinzari F, Caramanti M, Lauro R, Cardillo C. Metabolic and cardiovascular effects of ghrelin. Int J Pept 2010; 2010.
67. Lin Y, Matsumura K, Fukuhara M, et al. Ghrelin acts at the nucleus of the solitary tract to decrease arterial pressure in rats. Hypertension 2004; 43: 977-82.
68. Matsumura K, Tsuchihashi T, Fujii K, Abe I, Iida M. Central ghrelin modulates sympathetic activity in conscious rabbits. Hypertension 2002; 40: 694-9.
69. Russell RR, 3rd, Bergeron R, Shulman GI, Young LH. Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR. Am J Physiol 1999; 277: H643-9.
70. Russell RR, 3rd, Li J, Coven DL, et al. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest 2004; 114: 495-503.
71. Wiley KE, Davenport AP. Comparison of vasodilators in human internal mammary artery: ghrelin is a potent physiological antagonist of endothelin-1. Br J Pharmacol 2002; 136: 1146-52.
72. Tesauro M, Schinzari F, Iantorno M, et al. Ghrelin improves endothelial function in patients with metabolic syndrome. Circulation 2005; 112: 2986-92.
73. Iantorno M, Chen H, Kim JA, et al. Ghrelin has novel vascular actions that mimic PI 3-kinase-dependent actions of insulin to stimulate production of NO from endothelial cells. Am J Physiol Endocrinol Metab 2007; 292: E756-64.
74. Tesauro M, Schinzari F, Rovella V, et al. Ghrelin restores the endothelin 1/nitric oxide balance in patients with obesity-related metabolic syndrome. Hypertension 2009; 54: 995-1000.
75. Okumura H, Nagaya N, Enomoto M, et al. Vasodilatory effect of ghrelin, an endogenous peptide from the stomach. J Cardiovasc Pharmacol 2002; 39: 779-83.
76. Shinde UA, Desai KM, Yu C, Gopalakrishnan V. Nitric oxide synthase inhibition exaggerates the hypotensive response to ghrelin: role of calcium-activated potassium channels. J Hypertens 2005; 23: 779-84.
77. Volterrani M, Manelli F, Cicoira M, Lorusso R, Giustina A. Role of growth hormone in chronic heart failure. Therapeutic implications. Drugs 2000; 60: 711-9.
78. Hasdai D, Rizza RA, Holmes DR, Jr., et al. Insulin and insulin-like growth factor-I cause coronary vasorelaxation in vitro. Hypertension 1998; 32: 228-34.
79. Khorsandi MJ, Fagin JA, Giannella-Neto D, Forrester JS, Cercek B. Regulation of insulin-like growth factor-I and its receptor in rat aorta after balloon denudation. Evidence for local bioactivity. J Clin Invest 1992; 90: 1926-31.
80. Walsh MF, Barazi M, Pete G, et al. Insulin-like growth factor I diminishes in vivo and in vitro vascular contractility: role of vascular nitric oxide. Endocrinology 1996; 137: 1798-803.
81. Boger RH, Skamira C, Bode-Boger SM, et al. Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. A doubleblind, placebo-controlled study. J Clin Invest 1996; 98: 2706-13.
82. Isenovic ER, Divald A, Milivojevic N, et al. Interactive effects of insulin-like growth factor-1 and beta-estradiol on endothelial nitric oxide synthase activity in rat aortic endothelial cells. Metabolism 2003; 52: 482-7.
83. Sudar E, Dobutovic B, Soskic S, et al. Regulation of inducible nitric oxide synthase activity/expression in rat hearts from ghrelintreated rats. J Physiol Biochem 2010.
84. Dembinski A, Warzecha Z, Ceranowicz P, et al. Variable effect of ghrelin administration on pancreatic development in young rats. Role of insulin-like growth factor-1. J Physiol Pharmacol 2005; 56: 555-70.
85. Osterziel KJ, Strohm O, Schuler J, et al. Randomised, doubleblind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 1998; 351: 1233-7.
86. Pecker F. Ghrelin in the heart and growth hormone: which is chicken, which is egg? Cardiovasc Res 2004; 62: 442-3.
87. Amato G, Carella C, Fazio S, et al. Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. J Clin Endocrinol Metab 1993; 77: 1671-6.
88. Anker SD, Chua TP, Ponikowski P, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997; 96: 526-34.
89. Niebauer J, Pflaum CD, Clark AL, et al. Deficient insulin-like growth factor I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation. J Am Coll Cardiol 1998; 32: 393-7.
90. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006; 113: 1888-904.
91. Plum L, Belgardt BF, Bruning JC. Central insulin action in energy and glucose homeostasis. J Clin Invest 2006; 116: 1761-6.
92. Isenovic E, Walsh MF, Muniyappa R, et al. Phosphatidylinositol 3-kinase may mediate isoproterenol-induced vascular relaxation in part through nitric oxide production. Metabolism 2002; 51: 380-6.
93. Isenovic ER, Meng Y, Divald A, Milivojevic N, Sowers JR. Role of phosphatidylinositol 3-kinase/Akt pathway in angiotensin II and insulin-like growth factor-1 modulation of nitric oxide synthase in vascular smooth muscle cells. Endocrine 2002; 19: 287-92.
94. Poykko SM, Kellokoski E, Horkko S, et al. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 2003; 52: 2546-53.
95. Broglio F, Arvat E, Benso A, et al. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab 2001; 86: 5083-6.
96. Broglio F, Arvat E, Benso A, et al. Endocrine activities of cortistatin-14 and its interaction with GHRH and ghrelin in humans. J Clin Endocrinol Metab 2002; 87: 3783-90.
97. Broglio F, Benso A, Castiglioni C, et al. The endocrine response to ghrelin as a function of gender in humans in young and elderly subjects. J Clin Endocrinol Metab 2003; 88: 1537-42.
98. Dezaki K, Hosoda H, Kakei M, et al. Endogenous ghrelin in pancreatic islets restricts insulin release by attenuating Ca2+ signaling in beta-cells: implication in the glycemic control in rodents. Diabetes 2004; 53: 3142-51.
99. Dezaki K, Sone H, Koizumi M, et al. Blockade of pancreatic isletderived ghrelin enhances insulin secretion to prevent high-fat dietinduced glucose intolerance. Diabetes 2006; 55: 3486-93.
100. Sun Y, Asnicar M, Saha PK, Chan L, Smith RG. Ablation of ghrelin improves the diabetic but not obese phenotype of ob/ob mice. Cell Metab 2006; 3: 379-86.
101. Colombo M, Gregersen S, Xiao J, Hermansen K. Effects of ghrelin and other neuropeptides (CART, MCH, orexin A and B, and GLP-1) on the release of insulin from isolated rat islets. Pancreas 2003; 27: 161-6.
102. Wierup N, Yang S, McEvilly RJ, Mulder H, Sundler F. Ghrelin is expressed in a novel endocrine cell type in developing rat islets and inhibits insulin secretion from INS-1 (832/13) cells. J Histochem Cytochem 2004; 52: 301-10.
103. Reimer MK, Pacini G, Ahren B. Dose-dependent inhibition by ghrelin of insulin secretion in the mouse. Endocrinology 2003; 144: 916-21.
104. Salehi A, Dornonville de la Cour C, Hakanson R, Lundquist I. Effects of ghrelin on insulin and glucagon secretion: a study of isolated pancreatic islets and intact mice. Regul Pept 2004; 118: 143-50.
105. Wierup N, Svensson H, Mulder H, Sundler F. The ghrelin cell: a novel developmentally regulated islet cell in the human pancreas. Regul Pept 2002; 107: 63-9.
106. van der Lely AJ. Ghrelin and new metabolic frontiers. Horm Res 2009; 71 Suppl 1: 129-33.
107. Ahima RS. Ghrelin--a new player in glucose homeostasis? Cell Metab 2006; 3: 301-2.
108. Damjanovic SS, Lalic NM, Pesko PM, et al. Acute effects of ghrelin on insulin secretion and glucose disposal rate in gastrectomized patients. J Clin Endocrinol Metab 2006; 91: 2574-81.
109. Broglio F, Gottero C, Prodam F, et al. Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans. J Clin Endocrinol Metab 2004; 89: 3062-5.
110. Ariyasu H, Takaya K, Tagami T, et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelinlike immunoreactivity levels in humans. J Clin Endocrinol Metab 2001; 86: 4753-8.
111. Sudo T, Ishiyama K, Takemoto M, et al. Pancreatic endocrine function after total gastrectomy and truncal vagotomy. American journal of surgery 1982; 144: 539-44.
112. Muller AF, Janssen JA, Hofland LJ, et al. Blockade of the growth hormone (GH) receptor unmasks rapid GH-releasing peptide-6-mediated tissue-specific insulin resistance. J Clin Endocrinol Metab 2001; 86: 590-3.
113. Nordback I, Harju E. Immediate effect of vagotomy on pancreatic insulin secretion. Gut 1991; 32: 303-5.
114. Takaya K, Ariyasu H, Kanamoto N, et al. Ghrelin strongly stimulates growth hormone release in humans. J Clin Endocrinol Metab 2000; 85: 4908-11.
115. Fineberg SE, Merimee TJ. Acute metabolic effects of human growth hormone. Diabetes 1974; 23: 499-504.
116. O'Neal DN, Kalfas A, Dunning PL, et al. The effect of 3 months of recombinant human growth hormone (GH) therapy on insulin and glucose-mediated glucose disposal and insulin secretion in GHdeficient adults: a minimal model analysis. J Clin Endocrinol Metab 1994; 79: 975-83.
117. Foss MC, Saad MJ, Paccola GM, et al. Peripheral glucose metabolism in acromegaly. J Clin Endocrinol Metab 1991; 72: 1048-53.
118. Hansen I, Tsalikian E, Beaufrere B, et al. Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action. Am J Physiol 1986; 250: E269-73.
119. Beard JC, Halter JB, Best JD, Pfeifer MA, Porte D, Jr. Dexamethasone-induced insulin resistance enhances B cell responsiveness to glucose level in normal men. Am J Physiol 1984; 247: E592-6.
120. Rebuffe-Scrive M, Krotkiewski M, Elfverson J, Bjorntorp P. Muscle and adipose tissue morphology and metabolism in Cushing's syndrome. J Clin Endocrinol Metab 1988; 67: 1122-8.
121. Popovic V, Miljic D, Pekic S, et al. Low plasma ghrelin level in gastrectomized patients is accompanied by enhanced sensitivity to the ghrelin-induced growth hormone release. J Clin Endocrinol Metab 2005; 90: 2187-91.
122. Eden Engstrom B, Burman P, Holdstock C, Karlsson FA. Effects of growth hormone (GH) on ghrelin, leptin, and adiponectin in GHdeficient patients. J Clin Endocrinol Metab 2003; 88: 5193-8.
123. Grinspoon S, Miller KK, Herzog DB, Grieco KA, Klibanski A. Effects of estrogen and recombinant human insulin-like growth factor-I on ghrelin secretion in severe undernutrition. J Clin Endocrinol Metab 2004; 89: 3988-93.
124. Lucidi P, Murdolo G, Di Loreto C, et al. Metabolic and endocrine effects of physiological increments in plasma ghrelin concentrations. Nutr Metab Cardiovasc Dis 2005; 15: 410-7.
125. Vestergaard ET, Gormsen LC, Jessen N, et al. Ghrelin infusion in humans induces acute insulin resistance and lipolysis independent of growth hormone signaling. Diabetes 2008; 57: 3205-10.
126. Theander-Carrillo C, Wiedmer P, Cettour-Rose P, et al. Ghrelin action in the brain controls adipocyte metabolism. J Clin Invest 2006; 116: 1983-93.
127. Barazzoni R, Bosutti A, Stebel M, et al. Ghrelin regulates mitochondrial-lipid metabolism gene expression and tissue fat distribution in liver and skeletal muscle. Am J Physiol Endocrinol Metab 2005; 288: E228-35.
128. Varela L, Vazquez MJ, Cordido F, et al. Ghrelin and lipid metabolism: key partners in energy balance. J Mol Endocrinol 2011; 46: R43-63.
129. Nogueiras R, Lopez M, Dieguez C. Regulation of lipid metabolism by energy availability: a role for the central nervous system. Obes Rev 2010; 11: 185-201.
130. Sangiao-Alvarellos S, Vazquez MJ, Varela L, et al. Central ghrelin regulates peripheral lipid metabolism in a growth hormoneindependent fashion. Endocrinology 2009; 150: 4562-74.
131. Andrews ZB, Erion DM, Beiler R, et al. Uncoupling protein-2 decreases the lipogenic actions of ghrelin. Endocrinology 2010; 151: 2078-86.
132. Gormsen LC, Gjedsted J, Gjedde S, et al. Free fatty acids decrease circulating ghrelin concentrations in humans. Eur J Endocrinol 2006; 154: 667-73.
133. Vickers MH, Hofman PL, Gluckman PD, Lobie PE, Cutfield WS. Combination therapy with acipimox enhances the effect of growth hormone treatment on linear body growth in the normal and smallfor-gestational-age rat. Am J Physiol Endocrinol Metab 2006; 291: E1212-9.
134. Scacchi M, Orsini F, Cattaneo A, et al. The diagnosis of GH deficiency in obese patients: a reappraisal with GHRH plus arginine testing after pharmacological blockade of lipolysis. Eur J Endocrinol 2010; 163: 201-6.
135. Beaumont NJ, Skinner VO, Tan TM, et al. Ghrelin can bind to a species of high density lipoprotein associated with paraoxonase. J Biol Chem 2003; 278: 8877-80.
136. De Vriese C, Hacquebard M, Gregoire F, Carpentier Y, Delporte C. Ghrelin interacts with human plasma lipoproteins. Endocrinology 2007; 148: 2355-62.
137. Rizzo M, Amann-Vesti B, Zwimpfer C, Spinas G, Berneis K. Increased plasma resistin concentrations are associated with atherogenic small, dense low-density lipoproteins in patients with type-2 diabetes. Atherosclerosis 2010; 11: 66-7.
138. Rizzo M, Mikhailidis DP. There is more to predicting vascular disease than just established risk factors. Curr Pharm Des 2011; 17: 3608-10.
139. Kellokoski E, Kunnari A, Jokela M, et al. Ghrelin and obestatin modulate early atherogenic processes on cells: enhancement of monocyte adhesion and oxidized low-density lipoprotein binding. Metabolism 2009; 58: 1572-80.
140. Doogue MP, Begg EJ, Moore MP, et al. Metformin increases plasma ghrelin in Type 2 diabetes. Br J Clin Pharmacol 2009; 68: 875-82.
141. Kusaka I, Nagasaka S, Horie H, Ishibashi S. Metformin, but not pioglitazone, decreases postchallenge plasma ghrelin levels in type 2 diabetic patients: a possible role in weight stability? Diabetes Obes Metab 2008; 10: 1039-46.
142. Kiyici S, Ersoy C, Oz Gul O, et al. Total and acylated ghrelin levels in type 2 diabetic patients: similar levels observed after treatment with metformin, pioglitazone or diet therapy. Exp Clin Endocrinol Diabetes 2009; 117: 386-90.
143. Kadoglou NP, Tsanikidis H, Kapelouzou A, et al. Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus. Metabolism 2010; 59: 373-9.
144. Otto C, Otto B, Goke B, et al. Increase in adiponectin levels during pioglitazone therapy in relation to glucose control, insulin resistance as well as ghrelin and resistin levels. J Endocrinol Invest 2006; 29: 231-6.
145. Martin CK, Gupta AK, Smith SR, et al. Effect of pioglitazone on energy intake and ghrelin in diabetic patients. Diabetes Care 2010; 33: 742-4.
146. Rudovich N, Mohlig M, Otto B, et al. Effect of meglitinides on postprandial ghrelin secretion pattern in type 2 diabetes mellitus. Diabetes technology & therapeutics 2010; 12: 57-64.
147. Skoczylas A, Adamczak M, Chudek J, Wiecek A. Cilazapril increases plasma ghrelin concentration in obese patients with arterial hypertension. Endokrynol Pol 2010; 61: 21-7.
148. Otto C, Otto B, Frost RJ, et al. Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia. Acta diabetologica 2007; 44: 65-8.
149. Ozkan Y, Aydin S, Donder E, et al. Effect of orlistat on the total ghrelin and leptin levels in obese patients. J Physiol Biochem 2009; 65: 215-23.